Media Contact:

Bradley Patt, PhD
Tetrous, Inc.
818-645-4081
bpatt@tetrous.com

Product Information:

John Bojanowski
Tetrous, Inc.
978-809-0374
jbojanowski@tetrous.com

TETROUS® wins ACE Award at the American Orthopaedic Society for Sports Medicine (AOSSM) conference for its EnFix® implant

TETROUS® wins ACE Award at the American Orthopaedic Society for Sports Medicine (AOSSM) conference for its EnFix® implant

Los Angeles, CA, AUGUST 1, 2024 – The TETROUS EnFix implant was awarded the coveted ACE Award for “Accelerating the Cutting Edge” during the annual meeting of the American Orthopaedic Society for Sports Medicine (AOSSM) in Denver in July.

TETROUS, INC., was the sole recipient of this year’s ACE Award for “Accelerating the Cutting Edge” at the recent AOSSM annual conference held in Denver, CO. Although this honor is typically given to 2 or 3 innovative technologies in the industry, this year the committee stated the EnFix technology is a true “game changer” and presented Tetrous as the sole recipient.

“We are truly grateful for this award from AOSSM” stated Andy Carter, PhD, co-founder and CTO of Tetrous. He continued, “We have worked diligently in creating a technology that directly addresses the current high rate of failure in rotator cuff surgeries and other orthopedic procedures by remodeling the enthesis, the region where the tendon attaches to the bone. It is very rewarding that the industry is recognizing this unique technology.”

AOSSM Annual Conference

More than 500 EnFix RC® and EnFix TAC® have been implanted in a controlled release in the US and Australia over the past 12 months. Follow up MRIs on patients at six months post-surgery are consistently showing reformation of the enthesis, thickening of the tendon and little to no edema. While the majority of the procedures have been for rotator cuff, there are additional applications for this technology in hip, achilles and ACL procedures.

“We reviewed applications from a wide variety of companies for the 2024 ACE award,” stated Dr. Brian Busconi, orthopaedic surgeon and ACE award committee member. “After careful consideration and individual meetings with the finalists, we selected Tetrous as this year’s sole award winner. Their technology is truly innovative and a real game changer.”

Tetrous is actively expanding its distribution team in the US and adding new surgeons that have requested the EnFix implants for their rotator cuff surgeries. The Tetrous team will be attending the Shoulder and Elbow Society Association (SESA) meeting in Brisbane in October to further expand its business in Australia.

###

About Tetrous, Inc.

Founded in 2019, Tetrous, Inc. utilizes next generation advanced technologies for enthesis repair in sports medicine applications. The first offerings in the EnFix family of products are EnFix RC and EnFix TAC for rotator cuff repair. Tetrous was conceived from technology developed for spine surgery. The Company is employing and expanding the technology for novel applications in sports medicine. Its core technology has been used in over 150,000 implants in spine applications. Tetrous enjoys significant IP protection for its EnFix family of products with multiple issued patents and, additionally, has an exclusive license to the demineralized bone fiber technology used in its products for sports medicine applications from TheraCell, an ISTO Biologics Company.  

EnFix®, EnFix RC™ and EnFix TAC™ are trademarks of Tetrous, Inc.  
FormLok™ is a trademark of TheraCell, Inc., an Isto Biologics company.

For  more information visit www.tetrous.com and follow us on LinkedIn (www.linkedin.com/company/tetrous).

About Australian Biotechnologies

Australian Biotechnologies manufactures and distributes life enhancing allograft tissue products for the Australian community. The business was founded in 2000 and is located in Frenchs Forest, New South Wales, Australia. With world class processing facilities, specially trained technical staff and strict quality procedures, the company is the first privately owned and operated tissue-processing facility in Australia. 

Bradley E. Patt, PhD

Dr. Patt is cofounder chairman of Tetrous.

Brad has over 40 years experience as an entrepreneur and executive manager. He has led several enterprises from start-up phase through rapid growth and merger and acquisitions.

Brad founded several high tech ventures since 1997. He is currently co-founder chairman and CEO of TheraCell and DermOQ. Previously he was co-founder, CEO and Chairman of Gamma Medica, Inc. Brad built Gamma to market leadership position in pre­clinical CT, PET, SPECT imaging and is inventor and developer of Molecular Breast Imaging for detecting otherwise occult breast cancer in dense­breasted women.

Brad is currently co­founder and Chairman of DermOQ, Inc., an oxygen skin care company; EVO Worldwide, Inc. and spin off Smart Breast Corp., medical diagnostic imaging systems companies; and Hyvida Brands, a functional beverage startup. He is a director of High Beauty a cannabis cosmetic company. Brad also founded and is a Director of Thrive Outside the Box, a nonprofit organization that identifies and develops areas of talent in individuals on the autistic spectrum.

Brad is an internationally recognized authority in the field of medical imaging with over one hundred scientific papers and presentations, several book chapters, and over 20 patents. He has been an invited speaker at several international conferences. He has held elected positions on the IEEE Nuclear Medicine Instrumentation Steering Committee (NMISC) and the IEEE Radiation Instrumentation Steering Committee (RISC), and was appointed to the Program Committee of the SPIE Medical applications of Penetrating Radiation, acting as Chairman of the Penetrating Radiation Work Group for 2003 and 2004. Dr. Patt is a consultant to the National Institutes of Health and the recipient of over $15 million dollars of grant awards as Principal Investigator from the National Institutes of Health, The United States Department of Energy and NASA.

Bradley E. Patt, PhD

Dr. Patt is cofounder chairman of Tetrous. Brad has over 40 years experience as an entrepreneur and executive manager. He has led several enterprises from start-up phase through rapid growth and merger and acquisitions. Brad founded several high tech ventures since 1997. He is currently co-founder chairman and CEO of TheraCell and DermOQ. Previously he was co-founder, CEO and Chairman of Gamma Medica, Inc. Brad built Gamma to market leadership position in pre­clinical CT, PET, SPECT imaging and is inventor and developer of Molecular Breast Imaging for detecting otherwise occult breast cancer in dense­breasted women. Brad is currently co­founder and Chairman of DermOQ, Inc., an oxygen skin care company; EVO Worldwide, Inc. and spin off Smart Breast Corp., medical diagnostic imaging systems companies; and Hyvida Brands, a functional beverage startup. He is a director of High Beauty a cannabis cosmetic company. Brad also founded and is a Director of Thrive Outside the Box, a nonprofit organization that identifies and develops areas of talent in individuals on the autistic spectrum. Brad is an internationally recognized authority in the field of medical imaging with over one hundred scientific papers and presentations, several book chapters, and over 20 patents. He has been an invited speaker at several international conferences. He has held elected positions on the IEEE Nuclear Medicine Instrumentation Steering Committee (NMISC) and the IEEE Radiation Instrumentation Steering Committee (RISC), and was appointed to the Program Committee of the SPIE Medical applications of Penetrating Radiation, acting as Chairman of the Penetrating Radiation Work Group for 2003 and 2004. Dr. Patt is a consultant to the National Institutes of Health and the recipient of over $15 million dollars of grant awards as Principal Investigator from the National Institutes of Health, The United States Department of Energy and NASA.